close
  • Mega Menu Column
    • Facebook
    • Twitter
    • LinkedIn
    • Instagram
    • Donate
    • Become A Member
  • Home
  • About Us
    • Mission/Overview
    • Our Team
      • Board of Directors
      • Medical Advisors
      • Dental Advisory Council
      • Staff & Coaches
    • Financials
    • Contact Us
  • Living With P/P
    • Understanding P/P
    • All About Pemphigus (Patient Edition)
    • Diagnosis
    • Treatments
    • Physicians Referral
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
    • My Story
    • Ask A Coach
    • Discussion Forum
  • Research
    • 2018 Pre-IID Pemphigus and Pemphigoid Symposium
    • Research Grants
    • Clinical Trials
    • Natural History Study (Patient Registry)
    • Clinically Speaking
      • All About Pemphigus (Physician Edition)
      • Pemphigoid
      • Treatments
      • Complications & Side Effects
      • Risk Factors
      • Diagnostic Testing
      • Current Consensus of Disease Outcomes
      • Prevention & Psychology
  • Get Involved
    • Healing Heroes
    • Volunteer
    • Awareness
    • Support The IPPF
      • Make A Donation
      • Healing Heroes
      • Planned Giving
      • Other Ways To Give
    • #healourskin
    • Continuing Medical Education
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Ask A Coach
      • Local Support
    • Host A Fundraiser
    • Annual Patient Conferences
  • News
    • PemPress
    • Quarterly
    • Events
    • The Coaches Corner
  •  Facebook
  •  Twitter
  •  Instagram
  • DONATE
Pemphigus Pemphigoid Foundation logoPemphigus Pemphigoid Foundation logo
  • Menu
  • About Us
    • Mission/Overview
    • Our Team
      • Board of Directors
      • Medical Advisors
      • Dental Advisory Council
      • Staff & Coaches
    • Financials
    • Employment
    • Contact Us
  • Living With P/P
    • Understanding P/P
    • All About Pemphigus (Patient Edition)
    • Diagnosis
    • Treatments
    • Physicians Referral
    • Prescription Assistance
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
    • My Story
    • Ask A Coach
    • Discussion Forum
  • Research
    • 2018 Pre-IID Pemphigus and Pemphigoid Symposium
    • Research Grants
    • Clinical Trials
      • What is it?
      • Should I Volunteer?
      • What are my rights?
      • Definitions
    • Natural History Study (Patient Registry)
    • Clinically Speaking
      • All About Pemphigus (Physician Edition)
      • Pemphigoid
      • Treatments
      • Complications & Side Effects
      • Risk Factors
      • Diagnostic Testing
      • Current Consensus of Disease Outcomes
      • Prevention & Psychology
  • Get Involved
    • Healing Heroes
    • IPPF Web Store
    • Advocacy
      • Becoming a Self Advocate
      • Advocacy in Action!
      • Advocacy Tools and Resources
    • Awareness
    • Support The IPPF
      • Ways to Support
      • Make A Donation
      • Healing Heroes
      • Planned Giving
      • Host A Fundraiser
      • Volunteer
    • #healourskin
    • Continuing Medical Education
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
      • Ask A Coach
    • Annual Patient Conferences
  • News
    • PemPress
    • Quarterly
    • Events
    • The Coaches Corner

Matrix Metalloproteinases and Autoimmune Bulbous Diseases: Expression of MMP-2, -3, and -9 in Bullous Pemphigoid, Pemphigus Vulgaris, and Pemphigus Foliaceus.

By webadmin,

Posted by webadmin

On November 1, 2009

BACKGROUND: Matrix metalloproteinases (MMPs) participate in extracellular matrix degradation and may play an important role in basal membrane damage in many dermatologic diseases.

Recent studies implicated the importance of MMP-9 in the pathogenesis of bulla formation of bullous pemphigoid (BP). Various autoimmune bullous diseases are strongly associated with desmosome or hemidesmosome pathologies, and show an increased level of lesional MMP and exposed autoantigens from these structures. OBJECTIVE: This study evaluated the level of MMP-2, -3, and -9 in three types of autoimmune bullous disease [BP, pemphigus vulgaris (PV), pemphigus foliaceus (PF)] with the aim of investigating the role of MMPs in the pathogenesis of autoimmune bullous diseases. METHODS: Sample specimens were obtained from skin lesions of patients with BP (n=12), PV (n=10), and PF (n=12), and from normal controls (n=8). The immunohistochemical expression of MMP-2, -3, and -9 was analyzed and serum levels of MMP-2, -3, and -9 were measured by enzyme-linked immunosorbant assay (ELISA). The results were analyzed with reference to graded levels of clinical severity. RESULTS: Expression of dermal MMP-2, -3, and -9 were increased in BP, PV, and PF (p=0.036, 0.022, and 0.015, respectively). However, decreased expression of the three MMPs in the epidermis of skin lesions may have resulted from epidermal destruction. ELISA-determined serum levels of MMP-2, -3, and -9 increased in BP, PV and PF. Interestingly, MMP-2 was significantly increased in the sera of BP patients (p=0.015), consistent with the previous studies concerning the role of gelatinase (MMP-2 and -9) in the pathogenesis of BP. In BP patients, clinical severity was proportional to increased levels of MMP-2 in both skin lesions and and sera. CONCLUSION: The increased expression of MMP-2, -3, and -9 in skin lesions and sera may reflect the involvement of these enzymes in the mechanism of bulla formation in autoimmune bullous diseases including BP. In addition, expression of MMP and clinical severity may be closely connected.

Source: http://koreamed.org/SearchBasic.php?RID=526981&DT=1&QY=%22Korean+J+Dermatol%22+%5BJTI%5D++AND+2009+%5BDPY%5D

  • Facebook
  • Twitter
  • Google+
  • Pinterest
  • LinkedIn

Related

webadmin

Post navigation

← PreviousIndustry Years Behind on Testing Approved Drugs
NextCurrent Treatment of Autoimmune Blistering Diseases →
  • P/P Awareness Campaign
  • Disease Registry
  • Ask A Coach
  • Patients & Caregivers
  • For Medical Professionals
  • Clinical Trials
  • Treatments
  • @healourskin April 17, 2018

    The latest Pemphigus & Pemphigoid Weekly! paper.li/healourskin/13… Thanks to @diabetesfuna @GlobalGenes @Immunotx_papers #raredisease #nord

  • @healourskin April 11, 2018

    Save the date! 2018 Annual Patient Conference Raleigh-Durham, NC October 12-14 Hosted by Donna Culton, MD (UNC Depa… twitter.com/i/web/status/9…

  • @healourskin April 10, 2018

    The latest Pemphigus & Pemphigoid Weekly! paper.li/healourskin/13… Thanks to @HSP_90 @RareDiseases @ThriveChiroFL #nord #progress

  • @healourskin April 3, 2018

    The latest Pemphigus & Pemphigoid Weekly! paper.li/healourskin/13… Thanks to @RareDiseases @TregCellRadar @ImmunePharma #raredisease #nord

  • @healourskin March 29, 2018

    Checkout the latest from PemPress: Strategies for Managing Pemphigus and Pemphigoid ift.tt/2GgsIux… twitter.com/i/web/status/9…

  • Volunteer
  • Careers
  • Donate
  • News
  • PemPress
  • Forums
  • Contact

About IPPF

The International Pemphigus & Pemphigoid Foundation’s most important objectives are to provide patients and doctors worldwide with information about pemphigus and pemphigoid, and to provide patients and their caregivers much needed comfort and support so they can continue to live active, productive lives.
Read more »

Contact Us

International Pemphigus & Pemphigoid Foundation
1331 Garden Highway, Ste 100
Sacramento, CA 95833
United States of America

info@pemphigus.org
(855) 473-6744
(916) 922-1298

© 2017 International Pemphigus & Pemphigoid Foundation · All rights reserved.
Privacy Policy | Terms of Use | Sitemap
Website design and implementation by Uptown Studios.
en English
ar العربيةbn বাংলাzh-CN 简体中文en Englishfr Françaisde Deutschel Ελληνικάiw עִבְרִיתhi हिन्दीit Italianoja 日本語fa فارسیpt Portuguêspa ਪੰਜਾਬੀru Русскийes Españolth ไทยvi Tiếng Việt